Myers Scott Dunseth
Transaction: 06/16/2026
BUY
Change
+57,100
Price
Not reported
Filing
06/18/2026
Type
BUY
Zentalis Pharmaceuticals, Inc.
ZNTL • Biotechnology
$3.99
▼ -0.12 (-2.92%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$280.35M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.18Healthy liquidity · 6.93Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:30 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.99
Change-2.92%
Shares Out70.26M
Market Cap$280.35M
Enterprise Value$139.30M
52W Range1.21 - 6.95
Beta1.93
P/E-1.60
P/B1.95
P/FCF-1.74
EV/EBITDA-0.78
EV/FCF-0.86
Price$3.99
Change-2.92%
Shares Out70.26M
Market Cap$280.35M
Enterprise Value$139.30M
52W Range1.21 - 6.95
Beta1.93
P/E-1.60
P/B1.95
P/FCF-1.74
EV/EBITDA-0.78
EV/FCF-0.86
Earnings Yield-62.38%
FCF Yield-57.47%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.18
Current Ratio6.93
Quick Ratio6.93
Revenue 5Y-100.00%
Target$8.33
Target Upside108.77%
Target Median$10.00
Target Range5.00 - 10.00
Volume46.43K
Avg Volume1.17M
EPS Surprise-0.01
Investment DNA
How strong this company looks for long-term investors
48
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0.18Healthy liquidity · 6.93Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 12 analyst votes · 2026-09-05
83/100
Bullish
Bullish
8
Hold
4
Bearish
0
Price Target
2026-08-07
Low
$10.00
Mean
$10.00
Median
$10.00
High
$10.00
Insider Transactions
Recent executive and insider activity
Kariuki Enoch
Transaction: 06/16/2026
BUY
Change
+57,100
Price
Not reported
Filing
06/18/2026
Type
BUY
Walker Luke Nathaniel
Transaction: 06/16/2026
BUY
Change
+57,100
Price
Not reported
Filing
06/18/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Myers Scott Dunseth | BUY | +57,100 | Not reported | 06/16/2026 | 06/18/2026 |
| Kariuki Enoch | BUY | +57,100 | Not reported | 06/16/2026 | 06/18/2026 |
| Walker Luke Nathaniel | BUY | +57,100 | Not reported | 06/16/2026 | 06/18/2026 |
| Skvarka Jan | BUY | +57,100 | Not reported | 06/16/2026 | 06/18/2026 |
| Johnson David Michael | BUY | +57,100 | Not reported | 06/16/2026 | 06/18/2026 |
| Campbell Shannon | BUY | +114,200 | Not reported | 05/26/2026 | 05/27/2026 |
| Campbell Shannon | OTHER | 0 | Not reported | 05/22/2026 | 05/27/2026 |
| Vultaggio Vincent | SELL | -6,894 | $2.42 | 02/10/2026 | 02/10/2026 |
| EASTLAND JULIA MARIE | SELL | -889 | $2.39 | 02/09/2026 | 02/10/2026 |
| Vultaggio Vincent | SELL | -3,379 | $2.39 | 02/09/2026 | 02/10/2026 |
| Bruns Ingmar | SELL | -335 | $2.39 | 02/09/2026 | 02/10/2026 |
| EASTLAND JULIA MARIE | SELL | -7,866 | $2.43 | 02/06/2026 | 02/10/2026 |
| Vultaggio Vincent | SELL | -29,951 | $2.43 | 02/06/2026 | 02/10/2026 |
| Bruns Ingmar | SELL | -2,962 | $2.43 | 02/06/2026 | 02/10/2026 |
| Vultaggio Vincent | SELL | -556 | $2.52 | 02/03/2026 | 02/04/2026 |
| Vultaggio Vincent | SELL | -2,540 | $2.55 | 02/02/2026 | 02/04/2026 |
| EASTLAND JULIA MARIE | BUY | +775,000 | $2.84 | 01/08/2026 | 01/09/2026 |
| Bruns Ingmar | BUY | +365,000 | $2.84 | 01/08/2026 | 01/09/2026 |
| Bucher James B | BUY | +100,000 | $2.84 | 01/08/2026 | 01/09/2026 |
| Vultaggio Vincent | BUY | +100,000 | $2.84 | 01/08/2026 | 01/09/2026 |